REG - Trellus Health PLC - Company Update

Trellus HealthAnnouncement

21/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251021:nRSU1137Ea&default-theme=true

RNS Number : 1137E  Trellus Health PLC  21 October 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE MARKET ABUSE REGULATION (EU) 596/2014 AS AMENDED BY REGULATION 11 OF THE
MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019/310.  UPON THE
PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO
BE IN THE PUBLIC DOMAIN.

 

 

Trellus Health plc

("Trellus Health", the "Company" or the "Group")

 

Company Update

 

LONDON, U.K. AND NEW YORK, U.S. (21 October 2025). Trellus Health® plc (AIM:
TRLS), a healthcare company delivering Trellus Elevate®, a digital platform
that integrates data analytics with personalised, scientifically proven
resilience programs and value-based solutions to manage complex chronic
conditions, announces an update to cash runway, contract negotiations and
fundraising discussions.

 

Cash Runway

As announced in the Company's interim results on 8 September 2025, the Company
held net cash of $1.6 million as at 30 June 2025, providing a cash runway to
early November 2025. Since then, the Board has implemented a number of
cost-saving measures, extending the Company's cash runway to early December
2025. In addition, the Company now expects to reduce its average monthly cash
burn from approximately $440,000 to around $395,000 going forward.

 

Contract Negotiations

As noted in the interim results, the Company had anticipated announcing at
least one new collaboration by November. Discussions regarding one
collaboration with a leading global CRO to support a mid-stage clinical trial
are in late stage contracting. In parallel, negotiations on a separate
collaboration with a second leading global CRO are progressing following the
Company recently being granted preferred vendor status ("PVS"). Whilst PVS is
not revenue generating in itself, being awarded this status by another leading
global CRO reinforces the strength and differentiation of Trellus Health's
offering in the clinical trials vertical, provides direct access to the CRO's
client base, and accelerates procurement and contracting timelines.

 

The Board continues to anticipate announcing at least one new collaboration
before the end of November.

 

Fundraising

As previously disclosed, the Board has been exploring options for a potential
equity fundraising to support the Company's next phase of growth. Discussions
with prospective investors remain ongoing. However, there can be no certainty
that any funding transaction will be concluded. No other near-term strategic
opportunities have been identified at this time and it is unlikely that any
can be identified before early December.

 

The Board will provide a further update on both the potential fundraising and
collaboration discussions in due course.

 

 

Enquiries:

 

 Trellus Health plc                                                     https://trellushealth.com/ (https://trellushealth.com/)

 Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder            Via Walbrook PR
 Joy Bessenger, Chief Financial Officer

 Singer Capital Markets
 Jen Boorer / James Todd / Patrick Weaver                              Tel: +44 (0)20 7496 3000

 Walbrook PR           Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                       (mailto:trellus@walbrookpr.com)
 Paul McManus / Lianne Applegarth /          Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/
 Alice Woodings                                                        +44 (0)7407 804 654

 

 

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based
innovative solutions and services, helping people with chronic conditions take
control of their health through a proven, scientifically validated
self-management solution and continuous, personalised support. Trellus
Health's approach empowers patients to better navigate the emotional and
physical challenges of their conditions, leading to significant cost savings,
enhanced treatment adherence, and long-term, sustainable health outcomes.

 

Trellus Health® integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate®, a whole-person technology-enhanced condition management
platform. The Company is initially focusing on chronic costly GI conditions
that have a high mental health burden, such as Inflammatory Bowel Disease
(IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted
in over 90% fewer hospitalisations and a reduction of over 70% in emergency
room visits. Given the common emotional and mental health struggles associated
with a variety of chronic conditions and therapeutic areas, Trellus Health®
considers its approach to have potential utility and demand across many
conditions.

 

The Company also offers Trellus TrialSet™, a solution for pharmaceutical
partners spanning clinical trials to commercialisation, applying the same
validated resilience science and platform to support trial success and
long-term patient engagement

 

The Company was founded by Icahn School of Medicine at Mount Sinai faculty
members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading
experts in treating both the physical and emotional impacts of IBD, with a
combined 50 years of pioneering whole-person healthcare innovation.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information, visit: www.trellushealth.com
(http://www.trellushealth.com)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFEEESSEISESS



            Copyright 2019 Regulatory News Service, all rights reserved